Opinion|Videos|May 26, 2025
April 2025 ACIP Recommendations and Other Updates
Author(s)Adam James, PharmD
A panelist discusses recent advancements in the respiratory syncytial virus (RSV) vaccine space, including the approval of Arexvy and Abrysvo for older adults and pregnant individuals, the development of promising mRNA and protein subunit vaccines for high-risk groups, and ongoing studies to optimize dosing schedules and booster needs, all aimed at reducing RSV-related hospitalizations and deaths.
Advertisement
Episodes in this series
Summary for Physicians:
Recent advancements in the RSV vaccine space include the following:
- Vaccine Approvals:
- Arexvy (GSK) and Abrysvo (Pfizer, Inc) have been approved for use in older adults (60 years and older) and pregnant individuals, offering protection to both adults and newborns through maternal antibodies.
- Vaccine Platforms:
- mRNA and protein subunit vaccines are showing promising results, particularly for high-risk groups such as infants, older adults, and immunocompromised individuals.
- Efficacy & Safety:
- Clinical trials demonstrate high efficacy in reducing severe RSV disease, with mild adverse effects such as injection site soreness and mild fever.
- Future Outlook:
- Ongoing studies aim to optimize dosing schedules and assess booster needs, with a focus on reducing RSV-related hospitalizations and deaths in vulnerable populations.
These advancements provide new options for protecting high-risk patients from RSV infection.
Advertisement
Related to this article
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
This quiz was created in collaboration with PTCE™.
Pharmacy professionals can leverage LinkedIn to build a professional brand, expand meaningful connections, share expertise, and create opportunities for career growth.
An Italian pharmacy student offers an inside look at pharmacy education in Italy, from admission and coursework to oral exams and professional training.
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
Advertisement
Advertisement
Trending on Pharmacy Times
1
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
2
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
3
Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?
4
Pharmacists Positioned as Key Educators as Monoclonal Antibodies Emerge as COVID-19 Immunization Option
5